sb 203580 has been researched along with farnesyl pyrophosphate in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (farnesyl pyrophosphate) | Trials (farnesyl pyrophosphate) | Recent Studies (post-2010) (farnesyl pyrophosphate) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 696 | 1 | 245 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Allen, WE; Campbell, M; Sawyer, C; Trimble, ER; Vanhaesebroeck, B | 1 |
1 other study(ies) available for sb 203580 and farnesyl pyrophosphate
Article | Year |
---|---|
Glucose-potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk between the PI3K and MAPK signaling pathways.
Topics: Alkyl and Aryl Transferases; Androstadienes; Anthracenes; Antibodies, Monoclonal; Cells, Cultured; Chemotaxis; Chromones; Class I Phosphatidylinositol 3-Kinases; Farnesyltranstransferase; Flavonoids; Glucose; Humans; Imidazoles; Isoenzymes; JNK Mitogen-Activated Protein Kinases; Lovastatin; MAP Kinase Kinase 4; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Morpholines; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Polyisoprenyl Phosphates; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; ras Proteins; Sesquiterpenes; Sirolimus; TOR Serine-Threonine Kinases; Wortmannin | 2004 |